Up to a $1.7 billion collaboration was terminated when Sanofi canceled an agreement with Lexicon Pharmaceuticals to develop Zynquista™ (sotagliflozin) after type 1 and type 2 diabetes candidate showed mixed results in three Phase III trials, including disappointing...
Fatima Arkin of Science writes that a prominent pediatrician and investigator in the Philippines was indicted over the failed and possibly improper testing of Dengvaxia in the Philippines. Dengvaxia was yanked from the market in 2017 due to safety issues. The...
Watch a video showcasing Rachele Berria, Global Vice President & Head of Medical Affairs with a focus on diabetes. Sanofi is partnering with the ADA and focusing increasingly on Real-World evidence to compliment clinical trials.
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
159 WEST BROADWAY SUITE 200 SALT LAKE CITY, UT 84101
Pin It on Pinterest